Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and ...

Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Deutsche Bank analyst Justin Bowers raised the firm’s price target on Bio-Techne (TECH) to $72 from $66 and keeps a Buy rating on the shares. The ...

In an effort to boost production of materials used in cell and gene therapy, Minneapolis-based life sciences company Bio-Techne Corp. is spending up to $50 million to create a new manufacturing ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

With its stock down 6.6% over the past month, it is easy to disregard Bio-Techne (NASDAQ:TECH). However, stock prices are usually driven by a company’s financials over the long term, which in this ...